These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22942562)

  • 21. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
    Marie JP; Vekhoff A; Pico JL; Guy H; Andremont A; Richet H
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():57-64. PubMed ID: 9688452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.
    Düzova A; Kutluk T; Kanra G; Büyükpamukçu M; Akyüz C; Seçmeer G; Ceyhan M
    Turk J Pediatr; 2001; 43(2):105-9. PubMed ID: 11432485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.
    Samonis G; Koutsounaki E; Karageorgopoulos DE; Mitsikostas P; Kalpadaki C; Bozionelou V; Bompolaki I; Sgouros J; Taktikou V; Falagas ME
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1389-98. PubMed ID: 22037822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.
    De Pauw BE; Deresinski SC; Feld R; Lane-Allman EF; Donnelly JP
    Ann Intern Med; 1994 May; 120(10):834-44. PubMed ID: 8154643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
    Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
    Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
    Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.
    Micozzi A; Nucci M; Venditti M; Gentile G; Girmenia C; Meloni G; Martino P
    Eur J Clin Microbiol Infect Dis; 1993 Jan; 12(1):1-8. PubMed ID: 8385015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
    Glauser MP; Brennscheidt U; Cornely O; Grigg A; Figuera A; Keyserling C; Trostmann U; Welling L; Tack K
    Clin Microbiol Infect; 2002 Jan; 8(1):14-25. PubMed ID: 11906496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients.
    Velasco E; Costa MA; Martins CA; Nucci M
    Am J Clin Oncol; 1995 Oct; 18(5):429-35. PubMed ID: 7572762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
    Leoni F; Ciolli S; Pascarella A; Fanci R; Caporale R; Rossi Ferrini P
    Chemotherapy; 1993; 39(2):147-52. PubMed ID: 8458248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward].
    Shichmanter R; Miller EB; Shtalrid M; Landau Z
    Harefuah; 2010 Dec; 149(12):765-8, 813, 812. PubMed ID: 21916097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin.
    Gibson J; Date L; Joshua DE; Young GA; Wilson A; Benn R; Benson W; Iland H; Vincent PC; Kronenberg H
    Aust N Z J Med; 1989 Oct; 19(5):417-25. PubMed ID: 2686610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.